You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hodgkin

Showing 26 - 50 of 4,441
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma Trial (Tislelizumab, AVD, Radiotherapy)

Not yet recruiting
  • Hodgkin Lymphoma
  • Tislelizumab, AVD, Radiotherapy
  • (no location specified)
Nov 15, 2022

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Myocardial Injury in Hodgkin Lymphoma (HL) Survivors

Active, not recruiting
  • Hodgkin Lymphoma Survivor
  • Clinical Assessment
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 22, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Immunogenicity of COVID-19 Vaccinations in Autologous HSCT

Not yet recruiting
  • COVID-19
  • +2 more
    • Cologne, NRW, Germany
      University Hospital of Cologne
    Oct 27, 2022

    Hodgkin Lymphoma Trial in Moscow (Nivolumab)

    Recruiting
    • Hodgkin Lymphoma
    • Moscow, Russian Federation
      National Research Center for Hematology
    Dec 13, 2022

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Jan 4, 2023

    Non Hodgkin Lymphoma Trial in Philadelphia (Pembrolizumab)

    Recruiting
    • Non Hodgkin Lymphoma
    • Philadelphia, Pennsylvania
      Abamson Cancer Center of the University of Pennsylvania
    Jan 9, 2023

    Cardiovascular Disease in Hodgkin Lymphoma Survivors

    Not yet recruiting
    • Hodgkin Lymphoma
    • +3 more
    • Patient Self Reporting
    • +2 more
    • (no location specified)
    Jan 20, 2023

    Hodgkin Disease Trial in France (Morphological and functional magnetic resonance imaging (MRI), Neuropsychological assessment)

    Not yet recruiting
    • Hodgkin Disease
    • Morphological and functional magnetic resonance imaging (MRI)
    • Neuropsychological assessment
    • Arras, France
    • +3 more
    Oct 31, 2023

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

    Enrolling by invitation
    • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Mar 22, 2023

    Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

    Recruiting
    • Lymphoma
    • +2 more
    • Shanghai, Shanghai, China
    • +2 more
    May 9, 2023

    Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

    Not yet recruiting
    • Advanced Solid Tumor
    • Refractory Non-Hodgkin Lymphoma
    • (no location specified)
    May 28, 2023

    Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,

    Recruiting
    • Advanced Solid Tumors
    • +2 more
    • GIC-102 (Allogeneic NK cells)
    • Gyeonggi-do, Korea, Republic of
    • +3 more
    May 18, 2023

    Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

    Recruiting
    • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
    • dualCAR-NK19/70 cell
    • Shanghai, Shanghai, China
      Shanghai Tongji Hospital, Tongji University School of Medicine
    Apr 24, 2023

    Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

    Not yet recruiting
    • Lymphoma, Non-Hodgkin's, Adult
    • (no location specified)
    Aug 4, 2023

    Non-Hodgkin Lymphoma Trial in Sohag (real time pcr)

    Not yet recruiting
    • Non-Hodgkin Lymphoma
    • real time pcr
    • Sohag, Egypt
      Sohag University
    Jun 27, 2023

    Resting Heart Rate and Heart Rate Variability in Survivors of

    Active, not recruiting
    • Hodgkin Disease
      • Memphis, Tennessee
        Kirsten Ness
      Jan 23, 2023

      Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)

      Not yet recruiting
      • Leukemia, Acute Lymphoblastic
      • Lymphoma, Non-Hodgkin
      • CART-19
      • Ribeirao Preto, Sao Paulo, Brazil
        Ribeirao Preto School of Medicine, University of Sao Paulo
      Oct 23, 2023

      Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)

      Not yet recruiting
      • Lymphoma, Non-Hodgkin
      • +2 more
      • New York, New York
        Weill Cornell Medicine/NewYork-Presberteryian Hospital
      Jan 18, 2023

      Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

      Suspended
      • Recurrent Aggressive Non-Hodgkin Lymphoma
      • +5 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Jan 12, 2023

      Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)

      Recruiting
      • Hodgkin Lymphoma
      • Saint Petersburg, Russian Federation
      • +1 more
      Mar 3, 2023

      Non-hodgkin Lymphoma Trial (HY004)

      Not yet recruiting
      • Non-hodgkin Lymphoma
      • HY004
      • (no location specified)
      Aug 21, 2023

      Lymphoma, Non-Hodgkin Trial in China (DZD8586)

      Recruiting
      • Lymphoma, Non-Hodgkin
      • Beijing, Beijing, China
      • +5 more
      Apr 25, 2023

      Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

      Active, not recruiting
      Has Results
      • Follicular Lymphoma
      • +2 more
      • Laboratory Biomarker Analysis
      • Pembrolizumab
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Dec 6, 2022